SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging

项目摘要 淀粉样蛋白PET是阿尔茨海默病（AD）的生物学定义的核心，并且已经被大量整合到阿尔茨海默病（AD）的诊断中。 自2004年第一次PIB-PET扫描以来，SCAN-Amyloid Legacy（SCAN-AL）项目 将利用已经建立的研究计划（SCAN，NACC，LONI）沿着广泛的工作， 在过去的15年里，在ADRC现场一级进行了实施和收集昂贵的， ADRC研究参与者的有价值的淀粉样蛋白PET数据这项工作的最终目标是策划和 协调ADRC站点收集的现有淀粉样蛋白PET数据，以创建大规模资源 可以传播到ADRC社区用于各种研究工作。更 具体来说，在此期间，我们的目标是策划3000淀粉样蛋白PET扫描，这是类似于 目前通过ADNI可获得的淀粉样蛋白PET扫描的数量，并将此数据与已经获得的广泛数据联系起来， 这些参与者的可用数据（临床和认知数据、生物流体数据、尸检数据等）。而 母公司SCAN奖专注于利用严格的标准化处理前瞻性PET和MRI数据 方法在图像采集和采集后处理，SCAN-AL将允许更多的灵活性， 实现在尽可能多的独特ADRC临床核心上获得遗留淀粉样蛋白PET数据的特定目标 尽可能的参与者。这项工作意义重大，因为我们正在迅速接近2025年，仍然缺乏一个 AD的疾病改善治疗。本文提出的数据利用扩展了 相当多的资金已被用于AD的队列研究，以实现这一目标， 到2025年治愈AD。增加ADRC中预先存在的淀粉样蛋白PET数据集的利用率， 鉴于ADRC的异质性，与其他大规模的努力（如ADNI）相比， 参与者在临床诊断和人口统计学方面。而ADNI特别关注正常的 年龄，轻度认知障碍（MCI）和AD诊断，ADRC计划招募参与者跨越一个 反映当地研究者的重点和专业知识的一系列神经退行性疾病，如血管 疾病、额颞叶痴呆、进行性核上性麻痹、皮质基底综合征、帕金森氏症等。 此外，ADRC计划的独特之处在于，广泛的人口统计数据，包括种族，民族和年龄 都反映出来了。我们预计，SCAN-AL项目将有助于及时的科学机会， 血浆AD生物标志物的验证，支持需要大型数据集的创新分析， 遗传学和机器学习，以及使罕见的表型，难以调查 仅在一个站点收集。这项工作将为反倾销调查人员提供充足的机会，并补充 SCAN倡议的努力。

PROJECT SUMMARY Amyloid PET is central to a biological definition of Alzheimer’s disease (AD) and has been integrated heavily into the research setting since the first PIB-PET scans in 2004. The SCAN-Amyloid Legacy (SCAN-AL) Project will leverage already established research programs (SCAN, NACC, LONI) along with extensive work that has been conducted over the previous 15 years at the ADRC site level to implement and collect expensive and valuable amyloid PET data on ADRC research participants. The ultimate goal of this effort is to curate and harmonize pre-existing amyloid PET data collected across ADRC sites to create a large-scale resource that can be disseminated to the ADRC community for use in various research endeavors. More specifically, during this award period we will aim to curate 3000 amyloid PET scans, which is similar to the number of amyloid PET scans currently available through ADNI, and to link this data to extensive data already available on these participants (clinical and cognitive data, biofluid data, postmortem data, etc). Whereas the parent SCAN award focuses on processing of prospective PET and MRI data utilizing rigorous standardization methods both during image acquisition and post-acquisition processing, SCAN-AL will allow more flexibility to enable the specific goal of obtaining legacy amyloid PET data on as many unique ADRC Clinical Core participants as possible. This work is significant because we are quickly approaching 2025 and still lack a disease modifying treatment for AD. The data leveraging proposed herein extends the value of the considerable funding has been directed towards cohort studies of AD to contribute towards this goal of curing AD by 2025. Increasing the utilization of pre-existing amyloid PET dataset across ADRCs is particularly significant and unique compared to other large-scale efforts such as ADNI, given the heterogeneity in ADRC participants both in terms of clinical diagnoses and demographics. Whereas ADNI focuses specifically on normal aging, mild cognitive impairment (MCI), and AD diagnoses, the ADRC program recruits participants spanning a range of neurodegenerative diseases that reflect the focus and expertise of local investigators, such as vascular disease, frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome, Parkinson’s, etc. Further, the ADRC program is unique in that a broad range of demographics regarding race, ethnicity, and age are reflected. We anticipate that the SCAN-AL Project will contribute to timely scientific opportunities related to the validation of plasma AD biomarkers, support innovative analyses that require large datasets such as work with genetics and machine learning, as well as enable the investigation of rare phenotypes that are difficult to collect at one site alone. This effort will provide ample opportunities to AD investigators and complement the efforts of the SCAN initiative.